Novo Nordisk AS NVO Q1 2026 Earnings Strong EPS Beat Driven by Obesity and Diabetes Portfolio CRVS Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Advances Pipeline RILYN Q1 2024 Earnings Negative EPS and Bond Price Movement Amid Operational Challenges NNOX Q4 2025 Earnings EPS Misses Estimates PreRevenue Status Continues NRP Q1 2026 Earnings Solid EPS Performance Amid Quiet Market SQFTP Q3 2023 Earnings Preferred Stock Reports Negative EPS Amidst Stable Performance